GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » ROA %

Ensol Biosciences (XKRX:140610) ROA % : -100.37% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Ensol Biosciences's annualized Net Income for the quarter that ended in Dec. 2023 was ₩-11,302.1 Mil. Ensol Biosciences's average Total Assets over the quarter that ended in Dec. 2023 was ₩11,260.4 Mil. Therefore, Ensol Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -100.37%.

The historical rank and industry rank for Ensol Biosciences's ROA % or its related term are showing as below:

XKRX:140610' s ROA % Range Over the Past 10 Years
Min: -100.37   Med: -49.68   Max: -34.47
Current: -100.37

During the past 10 years, Ensol Biosciences's highest ROA % was -34.47%. The lowest was -100.37%. And the median was -49.68%.

XKRX:140610's ROA % is ranked worse than
83.33% of 1536 companies
in the Biotechnology industry
Industry Median: -35.83 vs XKRX:140610: -100.37

Ensol Biosciences ROA % Historical Data

The historical data trend for Ensol Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences ROA % Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.72 -72.14 -70.19 -34.47 -100.37

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.72 -72.14 -70.19 -34.47 -100.37

Competitive Comparison of Ensol Biosciences's ROA %

For the Biotechnology subindustry, Ensol Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's ROA % falls into.



Ensol Biosciences ROA % Calculation

Ensol Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-11302.099/( (13126.217+9394.57)/ 2 )
=-11302.099/11260.3935
=-100.37 %

Ensol Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Dec. 2023 ))/ count )
=-11302.099/( (13126.217+9394.57)/ 2 )
=-11302.099/11260.3935
=-100.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Ensol Biosciences  (XKRX:140610) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-11302.099/11260.3935
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-11302.099 / 176.545)*(176.545 / 11260.3935)
=Net Margin %*Asset Turnover
=-6401.82 %*0.0157
=-100.37 %

Note: The Net Income data used here is one times the annual (Dec. 2023) net income data. The Revenue data used here is one times the annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Ensol Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines